company background image
IDIA logo

Idorsia SWX:IDIA Stock Report

Last Price

CHF2.05

Market Cap

CHF367.0m

7D

-15.3%

1Y

-78.9%

Updated

14 Apr, 2024

Data

Company Financials +

IDIA Stock Overview

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland.

IDIA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Idorsia Ltd Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Idorsia
Historical stock prices
Current Share PriceCHF2.05
52 Week HighCHF9.94
52 Week LowCHF1.29
Beta0.82
1 Month Change12.56%
3 Month Change26.51%
1 Year Change-78.88%
3 Year Change-91.97%
5 Year Change-88.76%
Change since IPO-84.97%

Recent News & Updates

Recent updates

Industry Analysts Just Made A Captivating Upgrade To Their Idorsia Ltd (VTX:IDIA) Revenue Forecasts

Apr 05
Industry Analysts Just Made A Captivating Upgrade To Their Idorsia Ltd (VTX:IDIA) Revenue Forecasts

Need To Know: Analysts Are Much More Bullish On Idorsia Ltd (VTX:IDIA) Revenues

Mar 10
Need To Know: Analysts Are Much More Bullish On Idorsia Ltd (VTX:IDIA) Revenues

Idorsia Ltd (VTX:IDIA) Stock Catapults 38% Though Its Price And Business Still Lag The Industry

Mar 08
Idorsia Ltd (VTX:IDIA) Stock Catapults 38% Though Its Price And Business Still Lag The Industry

There's No Escaping Idorsia Ltd's (VTX:IDIA) Muted Revenues Despite A 37% Share Price Rise

Dec 28
There's No Escaping Idorsia Ltd's (VTX:IDIA) Muted Revenues Despite A 37% Share Price Rise

The Idorsia Ltd (VTX:IDIA) Analysts Have Been Trimming Their Sales Forecasts

Jul 27
The Idorsia Ltd (VTX:IDIA) Analysts Have Been Trimming Their Sales Forecasts

Idorsia Ltd's (VTX:IDIA) P/S Still Appears To Be Reasonable

Jun 14
Idorsia Ltd's (VTX:IDIA) P/S Still Appears To Be Reasonable

We Think Idorsia (VTX:IDIA) Has A Fair Chunk Of Debt

Apr 13
We Think Idorsia (VTX:IDIA) Has A Fair Chunk Of Debt

What You Need To Know About The Idorsia Ltd (VTX:IDIA) Analyst Downgrade Today

Feb 02
What You Need To Know About The Idorsia Ltd (VTX:IDIA) Analyst Downgrade Today

Is Idorsia (VTX:IDIA) Weighed On By Its Debt Load?

Dec 15
Is Idorsia (VTX:IDIA) Weighed On By Its Debt Load?

Is Idorsia (VTX:IDIA) Weighed On By Its Debt Load?

Sep 01
Is Idorsia (VTX:IDIA) Weighed On By Its Debt Load?

Need To Know: Analysts Are Much More Bullish On Idorsia Ltd (VTX:IDIA) Revenues

May 11
Need To Know: Analysts Are Much More Bullish On Idorsia Ltd (VTX:IDIA) Revenues

Is Idorsia (VTX:IDIA) Using Debt Sensibly?

May 03
Is Idorsia (VTX:IDIA) Using Debt Sensibly?

Analysts' Revenue Estimates For Idorsia Ltd (VTX:IDIA) Are Surging Higher

Feb 21
Analysts' Revenue Estimates For Idorsia Ltd (VTX:IDIA) Are Surging Higher

The Idorsia Ltd (VTX:IDIA) Analysts Have Been Trimming Their Sales Forecasts

Feb 07
The Idorsia Ltd (VTX:IDIA) Analysts Have Been Trimming Their Sales Forecasts

Here's What Idorsia Ltd's (VTX:IDIA) Shareholder Ownership Structure Looks Like

Jan 21
Here's What Idorsia Ltd's (VTX:IDIA) Shareholder Ownership Structure Looks Like

Did Idorsia's (VTX:IDIA) Share Price Deserve to Gain 25%?

Nov 29
Did Idorsia's (VTX:IDIA) Share Price Deserve to Gain 25%?

Shareholder Returns

IDIACH BiotechsCH Market
7D-15.3%18.0%-0.9%
1Y-78.9%21.6%-2.9%

Return vs Industry: IDIA underperformed the Swiss Biotechs industry which returned 21.6% over the past year.

Return vs Market: IDIA underperformed the Swiss Market which returned -2.9% over the past year.

Price Volatility

Is IDIA's price volatile compared to industry and market?
IDIA volatility
IDIA Average Weekly Movement22.7%
Biotechs Industry Average Movement7.6%
Market Average Movement3.5%
10% most volatile stocks in CH Market7.6%
10% least volatile stocks in CH Market1.9%

Stable Share Price: IDIA's share price has been volatile over the past 3 months.

Volatility Over Time: IDIA's weekly volatility has increased from 16% to 23% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017n/aJean-Paul Clozelwww.idorsia.com

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant), available in 25 and 50 mg, for the treatment of adult patients with insomnia.

Idorsia Ltd Fundamentals Summary

How do Idorsia's earnings and revenue compare to its market cap?
IDIA fundamental statistics
Market capCHF366.99m
Earnings (TTM)-CHF374.06m
Revenue (TTM)CHF184.69m

2.0x

P/S Ratio

-1.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IDIA income statement (TTM)
RevenueCHF184.69m
Cost of RevenueCHF349.11m
Gross Profit-CHF164.42m
Other ExpensesCHF209.63m
Earnings-CHF374.06m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

May 21, 2024

Earnings per share (EPS)-2.09
Gross Margin-89.03%
Net Profit Margin-202.54%
Debt/Equity Ratio-136.1%

How did IDIA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.